Hepatitis Monthly

Published by: Kowsar

The Association of Ala133Ser Polymorphism and Methylation in Ras Association Domain Family 1A Gene With Unfavorable Prognosis of Hepatocellular Carcinoma

Ying Feng 1 , Peng Li 1 , Yifei Liu 2 , Zhenyu Sha 3 , Liang Feng 1 , Fei Wang 1 , Qinsheng Mao 1 , * and Wanjiang Xue 1 , *
Authors Information
1 Department of General Surgery, Nantong University Affiliated Hospital, Nantong, China
2 Department of Pathology, Nantong University Affiliated Hospital, Nantong, China
3 Department of Medical Affairs, Nantong University Affiliated Hospital, Nantong, China
Corresponding Authors:
Article information
  • Hepatitis Monthly: October 01, 2015, 15 (10); e32145
  • Published Online: October 28, 2015
  • Article Type: Research Article
  • Received: August 6, 2015
  • Revised: September 7, 2015
  • Accepted: September 23, 2015
  • DOI: 10.5812/hepatmon.32145

To Cite: Feng Y, Li P, Liu Y, Sha Z, Feng L, et al. The Association of Ala133Ser Polymorphism and Methylation in Ras Association Domain Family 1A Gene With Unfavorable Prognosis of Hepatocellular Carcinoma, Hepat Mon. 2015 ; 15(10):e32145. doi: 10.5812/hepatmon.32145.

Copyright © 2015, Kowsar Corp. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
  • 1. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007; 132(7): 2557-76[DOI][PubMed]
  • 2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011; 61(2): 69-90[DOI][PubMed]
  • 3. Tanabe KK, Lemoine A, Finkelstein DM, Kawasaki H, Fujii T, Chung RT, et al. Epidermal growth factor gene functional polymorphism and the risk of hepatocellular carcinoma in patients with cirrhosis. JAMA. 2008; 299(1): 53-60[DOI][PubMed]
  • 4. Llovet JM, Fuster J, Bruix J, Barcelona-Clinic Liver Cancer G. The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transpl. 2004; 10(2 Suppl 1)-20[DOI][PubMed]
  • 5. Gordon M, Baksh S. RASSF1A: Not a prototypical Ras effector. Small GTPases. 2011; 2(3): 148-57[DOI][PubMed]
  • 6. Donninger H, Vos MD, Clark GJ. The RASSF1A tumor suppressor. J Cell Sci. 2007; 120: 3163-72[DOI][PubMed]
  • 7. van der Weyden L, Adams DJ. The Ras-association domain family (RASSF) members and their role in human tumourigenesis. Biochim Biophys Acta. 2007; 1776(1): 58-85[DOI][PubMed]
  • 8. Richter AM, Pfeifer GP, Dammann RH. The RASSF proteins in cancer; from epigenetic silencing to functional characterization. Biochim Biophys Acta. 2009; 1796(2): 114-28[DOI][PubMed]
  • 9. Ortiz-Vega S, Khokhlatchev A, Nedwidek M, Zhang XF, Dammann R, Pfeifer GP, et al. The putative tumor suppressor RASSF1A homodimerizes and heterodimerizes with the Ras-GTP binding protein Nore1. Oncogene. 2002; 21(9): 1381-90[DOI][PubMed]
  • 10. Hu L, Chen G, Yu H, Qiu X. Clinicopathological significance of RASSF1A reduced expression and hypermethylation in hepatocellular carcinoma. Hepatol Int. 2010; 4(1): 423-32[DOI][PubMed]
  • 11. Schagdarsurengin U, Wilkens L, Steinemann D, Flemming P, Kreipe HH, Pfeifer GP, et al. Frequent epigenetic inactivation of the RASSF1A gene in hepatocellular carcinoma. Oncogene. 2003; 22(12): 1866-71[DOI][PubMed]
  • 12. Schagdarsurengin U, Seidel C, Ulbrich EJ, Kolbl H, Dittmer J, Dammann R. A polymorphism at codon 133 of the tumor suppressor RASSF1A is associated with tumorous alteration of the breast. Int J Oncol. 2005; 27(1): 185-91[PubMed]
  • 13. Gao B, Xie XJ, Huang C, Shames DS, Chen TT, Lewis CM, et al. RASSF1A polymorphism A133S is associated with early onset breast cancer in BRCA1/2 mutation carriers. Cancer Res. 2008; 68(1): 22-5[DOI][PubMed]
  • 14. Bergqvist J, Latif A, Roberts SA, Hadfield KD, Lalloo F, Howell A, et al. RASSF1A polymorphism in familial breast cancer. Fam Cancer. 2010; 9(3): 263-5[DOI][PubMed]
  • 15. Donninger H, Barnoud T, Nelson N, Kassler S, Clark J, Cummins TD, et al. RASSF1A and the rs2073498 Cancer Associated SNP. Front Oncol. 2011; 1: 54[DOI][PubMed]
  • 16. Kanzaki H, Hanafusa H, Yamamoto H, Yasuda Y, Imai K, Yano M, et al. Single nucleotide polymorphism at codon 133 of the RASSF1 gene is preferentially associated with human lung adenocarcinoma risk. Cancer Lett. 2006; 238(1): 128-34[DOI][PubMed]
  • 17. Xiao G, Zhang T, Yao J, Ren J, Cao W, Wu G. The association between RASSF1 gene polymorphisms and lung cancer susceptibility among people in Hubei Province of China. J Huazhong Univ Sci Technolog Med Sci. 2009; 29(5): 646-9[DOI][PubMed]
  • 18. Zhou SL, Cui J, Fan ZM, Li XM, Li JL, Liu BC, et al. Polymorphism of A133S and promoter hypermethylation in Ras association domain family 1A gene (RASSF1A) is associated with risk of esophageal and gastric cardia cancers in Chinese population from high incidence area in northern China. BMC Cancer. 2013; 13: 259[DOI][PubMed]
  • 19. Kawai Y, Sakano S, Okayama N, Suehiro Y, Matsuyama H, Hinoda Y. Association of RASSF1A genotype and haplotype with the progression of clear cell renal cell carcinoma in Japanese patients. BJU Int. 2012; 110(7): 1070-5[DOI][PubMed]
  • 20. Bayram S. RASSF1A Ala133Ser polymorphism is associated with increased susceptibility to hepatocellular carcinoma in a Turkish population. Gene. 2012; 498(2): 264-9[DOI][PubMed]
  • 21. Meyer A, Coinac I, Bogdanova N, Dubrowinskaja N, Turmanov N, Haubold S, et al. Apoptosis gene polymorphisms and risk of prostate cancer: a hospital-based study of German patients treated with brachytherapy. Urol Oncol. 2013; 31(1): 74-81[DOI][PubMed]
  • 22. Shivakumar L, Minna J, Sakamaki T, Pestell R, White MA. The RASSF1A tumor suppressor blocks cell cycle progression and inhibits cyclin D1 accumulation. Mol Cell Biol. 2002; 22(12): 4309-18[PubMed]
  • 23. El-Kalla M, Onyskiw C, Baksh S. Functional importance of RASSF1A microtubule localization and polymorphisms. Oncogene. 2010; 29(42): 5729-40[DOI][PubMed]
  • 24. Bayram S. Association between RASSF1A Ala133Ser polymorphism and cancer susceptibility: a meta-analysis involving 8,892 subjects. Asian Pac J Cancer Prev. 2014; 15(8): 3691-8[PubMed]
  • 25. Qu LS, Liu JX, Liu TT, Shen XZ, Chen TY, Ni ZP, et al. Association of hepatitis B virus pre-S deletions with the development of hepatocellular carcinoma in Qidong, China. PLoS One. 2014; 9(5)[DOI][PubMed]
  • 26. Lee JH, Kim HY, Kim YJ, Yoon JH, Chung JW, Lee HS. Barcelona Clinic Liver Cancer staging system and survival of untreated hepatocellular carcinoma in a hepatitis B virus endemic area. J Gastroenterol Hepatol. 2015; 30(4): 696-705[DOI][PubMed]
  • 27. Burbee DG, Forgacs E, Zochbauer-Muller S, Shivakumar L, Fong K, Gao B, et al. Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. J Natl Cancer Inst. 2001; 93(9): 691-9[PubMed]
  • 28. Vera J, Schultz J, Ibrahim S, Raatz Y, Wolkenhauer O, Kunz M. Dynamical effects of epigenetic silencing of 14-3-3sigma expression. Mol Biosyst. 2010; 6(1): 264-73[DOI][PubMed]
  • 29. Kastan MB, Lim DS. The many substrates and functions of ATM. Nat Rev Mol Cell Biol. 2000; 1(3): 179-86[DOI][PubMed]
  • 30. Hamilton G, Yee KS, Scrace S, O'Neill E. ATM regulates a RASSF1A-dependent DNA damage response. Curr Biol. 2009; 19(23): 2020-5[DOI][PubMed]
  • 31. Smith J, Tho LM, Xu N, Gillespie DA. The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer. Adv Cancer Res. 2010; 108: 73-112[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments